Eisai Comes Into a Licensing Agreement with the Medac Regarding the Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
Eisai Co., Ltd. announced today that it has entered into a license agreement with medac Gesellschaft fur klinische Spezialpraparate mbH for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan. Medac is marketing this product…